GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.

New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.